Clinical trials: Disease-Free Survival
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
This is a Phase 3, randomized, open-label, multicenter study comparing rocbrutinib (LP-168) versus pirtobrutinib in adult participants with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), CLL, Refractory, CLL, Relapsed
- Trial name
- NCT07342478
- Testing
- Rocbrutinib, Pirtobrutinib
- Where
- 6 sites in United States
- Volunteers
- 306 people
- Sponsor
- Newave Pharmaceutical Inc
Colorectal Cancer, Oligometastatic Disease
RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer
This study aims to assess the clinical benefit of local ablative therapy (LAT) following initial standard first-line systemic treatment including the impact on survival, compared to continued standard first-line systemic…
- Trial name
- RESOLUTE (NCT05862051)
- Testing
- Local Ablative Therapy, Standard first-line systemic treatment
- Where
- 9 sites in Australia
- Volunteers
- 6 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Acute Lymphoblastic Leukemia
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.
- Trial name
- NCT02010931
- Where
- 10 sites in Czechia, France and 6 more
- Volunteers
- 310 people
- Sponsor
- Amgen
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Colorectal Cancer
Endoscopic Versus Surgical Treatment for T1 Colorectal Cancer
The implementation of population screening programs for colorectal cancer (CRC) has led to a considerable increase in the prevalence T1 CRC originating on polyps amenable by endoscopy.
- Trial name
- EpiT1 (NCT04150081)
- Testing
- Surgery or Endoscopic treatment
- Where
- Spain
- Volunteers
- 1,400 people
- Sponsor
- Hospital Clinic of Barcelona
Survival Outcomes of Patients With Pulmonary LCNEC
Overall Survival of Large Cell Neuroendocrine Lung Cancer Patients - a Retrospective Study
This is a retrospective study. 132 patients with LCNEC and combined LCNEC were included to the analysis. Patients were treated with radical, palliative or symptomatic intension between 2002-2018 in central and north-eastern…
- Trial name
- NCT03998332
- Volunteers
- 132 people
- Sponsor
- Jaroslaw B. Cwikla, MD, PhD, Professor UWM
Endocarditis
Stroke-free Survival Comparison Between Early Surgery and Conventional Therapy in Left Infective Endocarditis
The purpose of the EARLY study is to evaluate the efficacy and effectiveness of early surgery in patients with Infective Endocarditis (IE).
- Trial name
- NCT03411499
- Testing
- Early surgery, Conventional therapy
- Where
- Italy
- Volunteers
- 6 people
- Sponsor
- Maria Vittoria Hospital
Non-Hodgkin Lymphomas, Follicular Lymphomas
Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
The study addresses the question if the first line therapy of low malignant and mantle cell lymphomas with bendamustine plus rituximab is comparable (non inferior) with CHOP plus rituximab with regard to progression free survival…
- Conditions
- Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas
- Trial name
- NCT00991211
- Testing
- Bendamustine, Standard chemotherapy CHOP + Ritiximab
- Where
- Germany
- Volunteers
- 549 people
- Sponsor
- University of Giessen
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Non-Small -Cell Lung Cancer
A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer
A Randomized, Double-Blind, Multicenter, Phase 2 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small-Cell Lung Cancer…
- Trial name
- NCT01560104
- Testing
- Veliparib, Carboplatin, paclitaxel
- Volunteers
- 160 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
B-cell Acute Lymphoblastic Leukemia
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
The researchers are doing this study to find out whether PK-targeted fludarabine is an effective Lymphodepletion (LD) chemotherapy approach for people with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) who will…
- Trial name
- NCT07223021
- Testing
- Fludarabine, Cyclophosphamide, CAR-T
- Where
- 6 sites in United States, Netherlands
- Volunteers
- 130 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Patients Affected by Hepatocellular Carcinoma, Disease-Free Survival
Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC
Prognostic impact of AR vs NAR
- Conditions
- Patients Affected by Hepatocellular Carcinoma, Disease-Free Survival, Overall Survival
- Trial name
- ARversusNAR (NCT01236989)
- Testing
- anatomical liver resection, Non-anatomical liver resection
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- University of Milan
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
This is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
- Trial name
- Ven-BUCY (NCT07183878)
- Testing
- Venetoclax, Busulfan (BU)
- Where
- China
- Volunteers
- 138 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Endometrial Cancer
3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
To verify the safety of omission of lymph node dissection in ultra-low-risk endometrial cancer (KGOG criteria), we examine the survival of women with ultra-low-risk endometrial cancer who do not undergo lymph node dissection
- Trial name
- TREE PRO (NCT04227249)
- Testing
- no lymph node dissection
- Volunteers
- 153 people
- Sponsor
- Seoul National University Hospital
Melanoma, Surgery
Trial of Surgical Excision Margins in Thick Primary Melanoma
Objectives: The purpose of this study was to assess the effects of an excision margin of 2 cm versus 4 cm for patients with primary cutaneous malignant melanoma (CMM).
- Conditions
- Melanoma, Surgery, Treatment Outcome
- Trial name
- NCT01183936
- Testing
- 2-cm margin, 4-cm margin
- Volunteers
- 936 people
- Sponsor
- Karolinska Institutet
Thymoma and Thymic Carcinoma
6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors
This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB/B/C, AJCC TNM stage IIIA-IVA).
- Trial name
- NCT07463313
- Testing
- Cyclophosphamide, Doxorubicin, and Cisplatin (CAP), nab-Paclitaxel and Carboplatin
- Where
- China
- Volunteers
- 116 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Breast Cancer, HER2-positive Breast Cancer
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
This study is intended to carry out a single arm, prospective, open clinical study, and use Darsilide combined with endocrine therapy, Trastuzumab and Patuzumab to treat early or locally advanced breast cancer of TPBC before…
- Trial name
- NCT06276868
- Testing
- Dalcilib+letrozole+HP treatment group
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Henan Cancer Hospital
Non Small Cell Lung Cancer, Stage III Lung Cancer
Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLC
This study investigates whether postoperative radiotherapy (PORT) improves outcomes for patients with stage III non-small cell lung cancer (NSCLC) who have residual disease after neoadjuvant chemo-immunotherapy and surgery.
- Trial name
- RESCUE (NCT06878274)
- Testing
- Post-operative radiotherapy
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Bladder Cancer, Bladder Urothelial Carcinoma
A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival
The investigators would like to compare the progression free survival, overall survival, quality of life, and safety outcomes of patients receiving versus not receiving a 2nd transurethral resection of bladder tumor.
- Trial name
- RESECT (NCT03266900)
- Testing
- re-TURBT, 6 weeks BCG instillation
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto